At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,414 enrolled
Drug / intervention
Comparator: simvastatin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
In Brief
A Phase 3 clinical trial evaluating Comparator: simvastatin, MK-0524A, and 2 other interventions for Primary Hypercholesterolemia and Mixed Dyslipidemia. Completed, enrolled 2,414 participants.
Detailed Summary
This is a 20-week clinical trial in participants with primary hypercholesterolemia or mixed dyslipidemia to demonstrate the effect of MK-0524B compared to MK-0524A + Simvastatin on lipid values.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hypercholesterolemia, Mixed Dyslipidemia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJun 2007
Primary CompletionJun 2008
TodayJul 2026
First PostedMay 28, 2007
Enrollment StartJun 15, 2007
Primary CompletionJun 16, 2008
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 19.1 years ago
Interventions
Comparator: simvastatindrug
MK-0524Adrug
Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
Placebodrug
MK-0524Bdrug